December 03, 2025 - Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline

October 09, 2025 - Iolyx Therapeutics Announces Upcoming Presentation at Eyecelerator 2025 and Poster at the American Academy of Ophthalmology Annual Meeting

May 27, 2025 - Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease

WATCH a Webcast Replay of the Virtual R&D Update Event Led by KOLs

March 12, 2025 - Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences